Literature DB >> 24406078

MITF E318K's effect on melanoma risk independent of, but modified by, other risk factors.

Marianne Berwick1, Jamie MacArthur, Irene Orlow, Peter Kanetsky, Colin B Begg, Li Luo, Anne Reiner, Ajay Sharma, Bruce K Armstrong, Anne Kricker, Anne E Cust, Loraine D Marrett, Stephen B Gruber, Hoda Anton-Culver, Roberto Zanetti, Stefano Rosso, Richard P Gallagher, Terence Dwyer, Alison Venn, Klaus Busam, Lynn From, Kirsten White, Nancy E Thomas.   

Abstract

A rare germline variant in the microphthalmia-associated transcription factor (MITF) gene, E318K, has been reported as associated with melanoma. We confirmed its independent association with melanoma [odds ratio (OR) 1.7, 95% confidence interval (CI) = 1.1, 2.7, P = 0.03]; adjusted for age, sex, center, age × sex interaction, pigmentation characteristics, family history of melanoma, and nevus density). In stratified analyses, carriage of MITF E318K was associated with melanoma more strongly in people with dark hair than fair hair (P for interaction, 0.03) and in those with no moles than some or many moles (P for interaction, <0.01). There was no evidence of interaction between MC1R 'red hair variants' and MITF E318K. Moreover, risk of melanoma among carriers with 'low risk' phenotypes was as great or greater than among those with 'at risk' phenotypes with few exceptions.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Case-controlstudy; MITF; melanoma; risk factors; single nucleotide polymorphism

Mesh:

Substances:

Year:  2014        PMID: 24406078      PMCID: PMC3988207          DOI: 10.1111/pcmr.12215

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  16 in total

1.  A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma.

Authors:  Colin B Begg; Amanda J Hummer; Urvi Mujumdar; Bruce K Armstrong; Anne Kricker; Loraine D Marrett; Robert C Millikan; Stephen B Gruber; Hoda Anton Culver; Roberto Zanetti; Richard P Gallagher; Terrence Dwyer; Timothy R Rebbeck; Klaus Busam; Lynn From; Marianne Berwick
Journal:  Int J Epidemiol       Date:  2006-03-23       Impact factor: 7.196

2.  A note on the estimation of relative risks of rare genetic susceptibility markers.

Authors:  C B Begg; M Berwick
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1997-02       Impact factor: 4.254

3.  Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer.

Authors:  Rizwan Haq; David E Fisher
Journal:  J Clin Oncol       Date:  2011-06-13       Impact factor: 44.544

Review 4.  Fifteen-year quest for microphthalmia-associated transcription factor target genes.

Authors:  Yann Cheli; Mickael Ohanna; Robert Ballotti; Corine Bertolotto
Journal:  Pigment Cell Melanoma Res       Date:  2009-11-25       Impact factor: 4.693

Review 5.  Melanocyte development and malignant melanoma.

Authors:  C R Goding
Journal:  Forum (Genova)       Date:  2000 Jul-Sep

6.  Identification of a melanocyte-type promoter of the microphthalmia-associated transcription factor gene.

Authors:  N Fuse; K Yasumoto; H Suzuki; K Takahashi; S Shibahara
Journal:  Biochem Biophys Res Commun       Date:  1996-02-27       Impact factor: 3.575

7.  Melanoma risk associated with MC1R gene variants in Latvia and the functional analysis of rare variants.

Authors:  Aija Ozola; Kristīne Azarjana; Simona Doniņa; Guna Proboka; Ilona Mandrika; Ramona Petrovska; Ingrīda Cēma; Olita Heisele; Ludmila Eņģele; Baiba Streinerte; Dace Pjanova
Journal:  Cancer Genet       Date:  2013-03-20

8.  Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.

Authors:  F Demenais; H Mohamdi; V Chaudru; A M Goldstein; J A Newton Bishop; D T Bishop; P A Kanetsky; N K Hayward; E Gillanders; D E Elder; M F Avril; E Azizi; P van Belle; W Bergman; G Bianchi-Scarrà; B Bressac-de Paillerets; D Calista; C Carrera; J Hansson; M Harland; D Hogg; V Höiom; E A Holland; C Ingvar; M T Landi; J M Lang; R M Mackie; G J Mann; M E Ming; C J Njauw; H Olsson; J Palmer; L Pastorino; S Puig; J Randerson-Moor; M Stark; H Tsao; M A Tucker; P van der Velden; X R Yang; N Gruis
Journal:  J Natl Cancer Inst       Date:  2010-09-28       Impact factor: 13.506

9.  {alpha}MSH and Cyclic AMP elevating agents control melanosome pH through a protein kinase A-independent mechanism.

Authors:  Yann Cheli; Flavie Luciani; Mehdi Khaled; Laurent Beuret; Karine Bille; Pierre Gounon; Jean-Paul Ortonne; Corine Bertolotto; Robert Ballotti
Journal:  J Biol Chem       Date:  2009-04-22       Impact factor: 5.157

10.  MiTF regulates cellular response to reactive oxygen species through transcriptional regulation of APE-1/Ref-1.

Authors:  Feng Liu; Yan Fu; Frank L Meyskens
Journal:  J Invest Dermatol       Date:  2008-10-30       Impact factor: 8.551

View more
  12 in total

Review 1.  Paracrine regulation of melanocyte genomic stability: a focus on nucleotide excision repair.

Authors:  Stuart Gordon Jarrett; Katharine Marie Carter; John August D'Orazio
Journal:  Pigment Cell Melanoma Res       Date:  2017-04-20       Impact factor: 4.693

Review 2.  Update in genetic susceptibility in melanoma.

Authors:  Miriam Potrony; Celia Badenas; Paula Aguilera; Joan Anton Puig-Butille; Cristina Carrera; Josep Malvehy; Susana Puig
Journal:  Ann Transl Med       Date:  2015-09

Review 3.  Hormonal Regulation of the Repair of UV Photoproducts in Melanocytes by the Melanocortin Signaling Axis.

Authors:  Stuart G Jarrett; John A D'Orazio
Journal:  Photochem Photobiol       Date:  2016-11-17       Impact factor: 3.421

Review 4.  Germline mutations predisposing to melanoma.

Authors:  Atrin Toussi; Nicole Mans; Jeanna Welborn; Maija Kiuru
Journal:  J Cutan Pathol       Date:  2020-05-11       Impact factor: 1.587

5.  Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families.

Authors:  Thomas P Potjer; Sander Bollen; Anneliese J E M Grimbergen; Remco van Doorn; Nelleke A Gruis; Christi J van Asperen; Frederik J Hes; Nienke van der Stoep
Journal:  Int J Cancer       Date:  2019-01-21       Impact factor: 7.396

6.  Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients.

Authors:  Giulia Ciccarese; Bruna Dalmasso; William Bruno; Paola Queirolo; Lorenza Pastorino; Virginia Andreotti; Francesco Spagnolo; Enrica Tanda; Giovanni Ponti; Cesare Massone; Francesco Drago; Aurora Parodi; Giovanni Ghigliotti; Maria Antonietta Pizzichetta; Paola Ghiorzo
Journal:  J Transl Med       Date:  2020-02-13       Impact factor: 5.531

7.  Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma.

Authors:  Martin Lang; Cathy D Vocke; Christopher J Ricketts; Adam R Metwalli; Mark W Ball; Laura S Schmidt; William M Linehan
Journal:  Urology       Date:  2020-11-24       Impact factor: 2.649

8.  Expanding the phenotype of E318K (c.952G > A) MITF germline mutation carriers: case series and review of the literature.

Authors:  Leandro Jonata Carvalho Oliveira; Aline Bobato Lara Gongora; Fabiola Ambrosio Silveira Lima; Felipe Sales Nogueira Amorim Canedo; Carla Vanessa Quirino; Janina Pontes Pisani; Maria Isabel Achatz; Benedito Mauro Rossi
Journal:  Hered Cancer Clin Pract       Date:  2021-07-21       Impact factor: 2.857

Review 9.  Pediatric melanoma: incidence, treatment, and prognosis.

Authors:  Faiez K Saiyed; Emma C Hamilton; Mary T Austin
Journal:  Pediatric Health Med Ther       Date:  2017-04-18

10.  Assessing the Incremental Contribution of Common Genomic Variants to Melanoma Risk Prediction in Two Population-Based Studies.

Authors:  Anne E Cust; Martin Drummond; Peter A Kanetsky; Alisa M Goldstein; Jennifer H Barrett; Stuart MacGregor; Matthew H Law; Mark M Iles; Minh Bui; John L Hopper; Myriam Brossard; Florence Demenais; John C Taylor; Clive Hoggart; Kevin M Brown; Maria Teresa Landi; Julia A Newton-Bishop; Graham J Mann; D Timothy Bishop
Journal:  J Invest Dermatol       Date:  2018-06-08       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.